鳖甲化纤汤联合美能对慢性乙型肝炎肝纤维化指标及临床疗效的影响

Effect of decoction of turtle shell for anti-fibrosis combined with stronger neo-minophagen C on indices of hepatic fibrosis in chronic hepatitis B

目的:探讨鳖甲化纤汤联合美能对慢性乙型肝炎肝纤维化指标及临床疗效的影响。方法:应用随机分组方法,将94例慢性乙型肝炎患者随机分成2组:治疗组用美能100 mL加入10%葡萄糖250 mL内静脉滴注,1次/d,联合鳖甲化纤汤,1剂/d。对照组单纯用美能静脉滴注,1次/d,3个月为1疗程。治疗前后分别检测肝纤维化指标及肝功能等。结果:治疗组血清纤维化指标治疗前后变化及治疗后与对照组比有统计学意义(P<0.01)。肝功能指标治疗组治疗前后及治疗后与对照组比有统计学意义(P<0.01)。治疗组基本治愈率及总有效率(40%,84.0%)与对照组(27.27%,86.18%)比有统计学意义(P<0.05)。治疗后2组超声门脉直径及脾脏厚度变化比较治疗组明显优于对照组(P<0.01)。结论:鳖甲化纤汤联合美能治疗慢性乙型肝炎能显著改善肝纤维化及肝功能指标,提高临床疗效。

Objective:To evaluate the effect of decoction of turtle shell for anti-fibrosis combined with stronger neo-minophagen C on the indices of hepatic fibrosis in chronic hepatitis B.Method:The 94 cases of chronic viral hepatitis B patients were randomly divided into two groups.The treatment group was treated with stronger neo-minophagen C 100 mL dissolved in 10% dextrose 250ml once a day intravenously,combined with decoction of turtle shell for anti-fibrosis one powder daily.And the control group was treated with stronger neo-minophagen C alone,3 months as a course.Liver fibrosis indexes and liver function index were tested for two groups of patients before and after the treatment.Result:Both the difference of liver fibrosis indexes between the treatment group and the control group and before and after the treatment in the treatment group had statistical significance(P<0.01).Both the difference of liver function index between the treatment group and the control group and before and after the treatment in the treatment group had statistical significance(P<0.01).The basic cure rate and total effective rate were 40% and 84.0% in the treatment group and 27.27% and 86.18% in the control group respectively with significant difference.The treatment group was superior to control group in the mean size of diameter of portal vein and the thickness of spleen(P<0.01).Conclusion:Decoction of turtle shell for anti-fibrosis combined with stronger neo-minophagen C could significantly improve the clinical efficacy and the liver fibrosis indexes and liver function index in chronic hepatitis B.